ADIL has 36-month beta value of 1.12. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ADIL is 6.36M, and currently, short sellers hold a 0.32% ratio of that float. The average trading volume of ADIL on February 05, 2025 was 182.46K shares.
ADIL) stock’s latest price update
The stock price of Adial Pharmaceuticals Inc (NASDAQ: ADIL) has dropped by -5.92 compared to previous close of 0.83. Despite this, the company has seen a fall of -6.04% in its stock price over the last five trading days. globenewswire.com reported 2025-01-29 that Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions
ADIL’s Market Performance
Adial Pharmaceuticals Inc (ADIL) has seen a -6.04% fall in stock performance for the week, with a -26.46% decline in the past month and a -22.01% plunge in the past quarter. The volatility ratio for the week is 9.32%, and the volatility levels for the past 30 days are at 7.49% for ADIL. The simple moving average for the past 20 days is -18.08% for ADIL’s stock, with a -31.18% simple moving average for the past 200 days.
Analysts’ Opinion of ADIL
Many brokerage firms have already submitted their reports for ADIL stocks, with Rodman & Renshaw repeating the rating for ADIL by listing it as a “Buy.” The predicted price for ADIL in the upcoming period, according to Rodman & Renshaw is $8 based on the research report published on November 14, 2024 of the previous year 2024.
Maxim Group, on the other hand, stated in their research note that they expect to see ADIL reach a price target of $5. The rating they have provided for ADIL stocks is “Buy” according to the report published on October 30th, 2018.
ADIL Trading at -23.98% from the 50-Day Moving Average
After a stumble in the market that brought ADIL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -81.30% of loss for the given period.
Volatility was left at 7.49%, however, over the last 30 days, the volatility rate increased by 9.32%, as shares sank -28.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.78% lower at present.
During the last 5 trading sessions, ADIL fell by -6.04%, which changed the moving average for the period of 200-days by -66.38% in comparison to the 20-day moving average, which settled at $0.9521. In addition, Adial Pharmaceuticals Inc saw -22.78% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for ADIL
Current profitability levels for the company are sitting at:
- -252.05 for the present operating margin
- 0.99 for the gross margin
The net margin for Adial Pharmaceuticals Inc stands at -404.61. The total capital return value is set at -1.38. Equity return is now at value -316.95, with -272.04 for asset returns.
Currently, EBITDA for the company is -7.0 million with net debt to EBITDA at 0.63. When we switch over and look at the enterprise to sales, we see a ratio of -4.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.78.
Conclusion
To put it simply, Adial Pharmaceuticals Inc (ADIL) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
